OPEN END TURBO CALL WARRANT - ELI LILLY & CO | Real-time Bid/Ask 13:46:41 27/06/2024 BST | ||
| 2.98 CHF / 3 CHF | +0.67% |
|
| Current month | +32.59% | ||
| 1 month | +33.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 2.97 | -1.33% |
| 25/06/24 | 3.01 | +4.15% |
| 24/06/24 | 2.89 | +2.85% |
| 21/06/24 | 2.81 | -3.44% |
| 20/06/24 | 2.91 | +2.46% |
Delayed Quote Swiss Exchange
Last update June 26, 2024 at 04:20 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYD6U | |
| ISIN | CH1297146552 |
| Date issued | 09/10/2023 |
| Strike | 575.2 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.23 CHF |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.01 CHF |
|---|---|
| Lowest since issue | 0.18 CHF |
| Spread | 0.02 CHF |
| Spread % | 0.67% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- LLYD6U Certificat
